MX363845B - Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales. - Google Patents
Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales.Info
- Publication number
- MX363845B MX363845B MX2015010740A MX2015010740A MX363845B MX 363845 B MX363845 B MX 363845B MX 2015010740 A MX2015010740 A MX 2015010740A MX 2015010740 A MX2015010740 A MX 2015010740A MX 363845 B MX363845 B MX 363845B
- Authority
- MX
- Mexico
- Prior art keywords
- caix
- cancer treatment
- based cancer
- stratification based
- expression
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000013517 stratification Methods 0.000 title 1
- 108700012439 CA9 Proteins 0.000 abstract 6
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un anticuerpo anti-CAIX (anhidrasa carbónica IX) para usarse en el tratamiento de carcinoma de células claras renales (ccRCC), en donde el uso comprende cuantificar la expresión de CAIX en al menos una muestra de tumor proporcionada de un sujeto a ser tratado, determinar un puntaje de CAIX basado en la expresión de CAIX en la muestra de tumor, y el sujeto es tratado si es alcanzado un puntaje de CAIX = 2.6, en donde la expresión de CAIX es cuantificada por tinción inmunohistoquímica, y en donde el puntaje de CAIX se determina y/o calcular la fórmula: Puntaje de CAIX = ( 0 x porcentaje de células tumorales viables sin intensidad de tinción) + (1 x porcentaje de células tumorales viables con intensidad de tinción débil) + (2 x porcentaje de células tumorales viables con intensidad de tinción moderada) + (3x porcentaje de células tumorales viables con intensidad de tinción fuerte).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361768084P | 2013-02-22 | 2013-02-22 | |
US201361829349P | 2013-05-31 | 2013-05-31 | |
PCT/EP2014/053420 WO2014128258A1 (en) | 2013-02-22 | 2014-02-21 | Caix stratification based cancer treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015010740A MX2015010740A (es) | 2016-04-11 |
MX363845B true MX363845B (es) | 2019-04-05 |
Family
ID=50179596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015010740A MX363845B (es) | 2013-02-22 | 2014-02-21 | Anticuerpo anti-caix para usarse en el tratamiento de carcinoma de células claras renales. |
Country Status (17)
Country | Link |
---|---|
US (1) | US10620208B2 (es) |
EP (1) | EP2958589B1 (es) |
JP (1) | JP2016511766A (es) |
KR (1) | KR102172403B1 (es) |
CN (2) | CN110208535A (es) |
AU (1) | AU2014220705C1 (es) |
BR (1) | BR112015020061A8 (es) |
CA (1) | CA2901531C (es) |
ES (1) | ES2703572T3 (es) |
HK (1) | HK1215195A1 (es) |
IL (1) | IL240499B (es) |
MX (1) | MX363845B (es) |
NZ (1) | NZ712023A (es) |
RU (1) | RU2663694C2 (es) |
SG (1) | SG11201506635TA (es) |
WO (1) | WO2014128258A1 (es) |
ZA (1) | ZA201505937B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110208535A (zh) | 2013-02-22 | 2019-09-06 | 威丽克斯股份公司 | 基于caix分级的癌症治疗 |
EP4031667B1 (en) | 2019-09-16 | 2023-11-01 | Bracco Imaging SPA | Ca-ix aptamers and diagnostic and therapeutic uses thereof |
CN110862457B (zh) * | 2019-12-05 | 2021-09-24 | 中国人民解放军陆军特色医学中心 | 能与碳酸酐酶ix特异性结合的骆驼源纳米抗体及其应用 |
WO2024023144A1 (en) | 2022-07-28 | 2024-02-01 | Bracco Imaging Spa | Ca-ix targeting fluorescent probes |
WO2024023138A2 (en) | 2022-07-28 | 2024-02-01 | Bracco Imaging Spa | Ca-ix targeting fluorescent probes |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366707A1 (en) | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
US5981711A (en) | 1992-03-11 | 1999-11-09 | Institute Of Virology, Slovak Academy Of Sciences | MN-specific antibodies and hybridomas |
US6093548A (en) | 1992-03-11 | 2000-07-25 | Institute Of Virology, Slovak Academy Of Sciences | Detection and quantitation of MN-specific antibodies. |
US5989838A (en) | 1992-03-11 | 1999-11-23 | Institute Of Virology, Slovak Academy Of Sciences | Immunological methods of detecting MN proteins and MN polypeptides |
US5387676A (en) | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
WO1995034650A2 (en) | 1994-06-15 | 1995-12-21 | Ciba Corning Diagnostics Corp. | Mn gene and protein |
DK1123387T3 (da) | 1998-10-23 | 2008-02-25 | Inst Virology | MN-gen og protein |
AU2002238537B8 (en) | 2001-02-07 | 2006-08-24 | Wilex Ag | Hybridoma cell line G250 and its use for producing monoclonal antibodies |
WO2002098897A2 (en) * | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
CA2467738A1 (en) * | 2001-12-03 | 2003-06-12 | Abgenix, Inc. | Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
US7910549B2 (en) | 2001-12-13 | 2011-03-22 | Institute Of Virology Of The Slovak Academy Of Sciences | MN gene and protein |
DE60328477D1 (de) * | 2002-04-16 | 2009-09-03 | Univ California | Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix |
DE10240118A1 (de) | 2002-08-30 | 2004-03-11 | Wilex Ag | Verfahren zur Identifizierung von Nierenzellkarzinom spezifischen Proteinen und deren Verwendung |
KR101130181B1 (ko) * | 2003-02-27 | 2012-03-28 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 인플루엔자 바이러스 감염의 치료 및 검출에 유용한 핵산분자, 폴리펩티드, 항체 및 이를 포함하는 조성물 |
KR20120035234A (ko) * | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
JP4905957B2 (ja) | 2003-10-16 | 2012-03-28 | インスティトゥート オブ ヴァイロロジー | Mn/ca ixおよび癌予後診断 |
JP4426621B2 (ja) * | 2004-05-04 | 2010-03-03 | バイエル ヘルスケア エルエルシー | Mn/ca ix/ca9及び腎臓癌の予後診断 |
CA2566950A1 (en) * | 2004-07-02 | 2006-01-12 | Wilex Ag | Improved adjuvant therapy of g250-expressing tumors |
US7820159B2 (en) * | 2006-10-31 | 2010-10-26 | Instiute of Virology of the Slovak Academy of Sciences | MN/CA IX and EGFR pathway inhibition |
US8492520B2 (en) * | 2007-11-02 | 2013-07-23 | Wilex Ag | Binding epitopes for G250 antibody |
JP2011509304A (ja) * | 2008-01-09 | 2011-03-24 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 炭酸脱水酵素ixの阻害剤 |
US20120207672A1 (en) * | 2009-09-15 | 2012-08-16 | Wilex Ag | Selective detection of bone metastases in renal clear cell carcinoma |
WO2011139375A1 (en) * | 2010-05-06 | 2011-11-10 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against carbonic anhydrase ix and methods and uses thereof |
CN110208535A (zh) | 2013-02-22 | 2019-09-06 | 威丽克斯股份公司 | 基于caix分级的癌症治疗 |
-
2014
- 2014-02-21 CN CN201910448310.2A patent/CN110208535A/zh active Pending
- 2014-02-21 KR KR1020157025649A patent/KR102172403B1/ko active IP Right Grant
- 2014-02-21 AU AU2014220705A patent/AU2014220705C1/en active Active
- 2014-02-21 US US14/769,541 patent/US10620208B2/en active Active
- 2014-02-21 MX MX2015010740A patent/MX363845B/es active IP Right Grant
- 2014-02-21 CA CA2901531A patent/CA2901531C/en active Active
- 2014-02-21 NZ NZ71202314A patent/NZ712023A/en unknown
- 2014-02-21 RU RU2015140139A patent/RU2663694C2/ru active
- 2014-02-21 JP JP2015558463A patent/JP2016511766A/ja active Pending
- 2014-02-21 SG SG11201506635TA patent/SG11201506635TA/en unknown
- 2014-02-21 BR BR112015020061A patent/BR112015020061A8/pt not_active Application Discontinuation
- 2014-02-21 WO PCT/EP2014/053420 patent/WO2014128258A1/en active Application Filing
- 2014-02-21 EP EP14706543.7A patent/EP2958589B1/en active Active
- 2014-02-21 ES ES14706543T patent/ES2703572T3/es active Active
- 2014-02-21 CN CN201480018654.5A patent/CN105377295A/zh active Pending
-
2015
- 2015-08-10 IL IL240499A patent/IL240499B/en active IP Right Grant
- 2015-08-18 ZA ZA201505937A patent/ZA201505937B/en unknown
-
2016
- 2016-03-22 HK HK16103308.3A patent/HK1215195A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR102172403B1 (ko) | 2020-11-02 |
IL240499A0 (en) | 2015-09-24 |
AU2014220705A1 (en) | 2015-09-10 |
CA2901531A1 (en) | 2014-08-28 |
BR112015020061A8 (pt) | 2018-01-23 |
EP2958589A1 (en) | 2015-12-30 |
CA2901531C (en) | 2022-03-29 |
US10620208B2 (en) | 2020-04-14 |
AU2014220705B2 (en) | 2018-05-17 |
KR20150119406A (ko) | 2015-10-23 |
IL240499B (en) | 2020-02-27 |
CN105377295A (zh) | 2016-03-02 |
ZA201505937B (en) | 2019-10-30 |
US20160002350A1 (en) | 2016-01-07 |
SG11201506635TA (en) | 2015-09-29 |
NZ712023A (en) | 2019-10-25 |
MX2015010740A (es) | 2016-04-11 |
HK1215195A1 (zh) | 2016-08-19 |
WO2014128258A1 (en) | 2014-08-28 |
BR112015020061A2 (pt) | 2017-07-18 |
AU2014220705C1 (en) | 2018-10-18 |
ES2703572T3 (es) | 2019-03-11 |
EP2958589B1 (en) | 2018-11-21 |
CN110208535A (zh) | 2019-09-06 |
RU2663694C2 (ru) | 2018-08-08 |
JP2016511766A (ja) | 2016-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
NZ606725A (en) | Methods for predicting anti-cancer response | |
MX340453B (es) | Biomarcadores para cancer de pulmon. | |
WO2014160499A3 (en) | Methods and compositions for detecting pancreatic cancer | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
WO2014031859A3 (en) | Compositions and methods relating to blood-based biomarkers of breast cancer | |
EP2598873A4 (en) | BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM | |
NZ704718A (en) | Epcam aptamer for detection of cancer stem cells | |
WO2014133855A8 (en) | Tuberculosis biomarkers and uses thereof | |
MX356866B (es) | Biomarcadores p53. | |
NZ712023A (en) | Caix stratification based cancer treatment | |
NZ704719A (en) | Cd133 aptamers for detection of cancer stem cells | |
TR201909951T4 (tr) | Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem. | |
WO2014197835A3 (en) | Methods and compositions for the treatment of cancer | |
EA201401201A1 (ru) | Способ | |
MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
EA201301265A1 (ru) | Способ лечения солидных злокачественных опухолей, включая прогрессирующие или метастатические солидные злокачественные опухоли | |
MX2015010023A (es) | Anticuerpos anti-cd83 y su uso. | |
WO2013081645A3 (en) | Erbb3 mutations in cancer | |
MX363679B (es) | Metodo para diagnosticar cancer. | |
WO2012145399A3 (en) | Methods of diagnosing cancer in a patient | |
WO2013132354A3 (en) | Gene signatures associated with efficacy of postmastectomy radiotherapy in breast cancer | |
BR112015021846A2 (pt) | biomarcador | |
MA37475A1 (fr) | Biomarqueurs pour thérapie par inhibiteur de iap |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |